{"id":354693,"date":"2025-08-28T12:25:46","date_gmt":"2025-08-28T12:25:46","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/how-to-buy-royalty-pharma\/"},"modified":"2025-08-28T12:25:46","modified_gmt":"2025-08-28T12:25:46","slug":"how-to-buy-royalty-pharma","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-royalty-pharma\/","title":{"rendered":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Royalty Pharma plc (RPRX) &#8211; \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Royalty Pharma plc (RPRX)"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334117,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-354693","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"C\u00e1ch Mua C\u1ed5 Phi\u1ebfu Royalty Pharma plc (RPRX) - \u0110\u1ea7u T\u01b0 V\u00e0o C\u1ed5 Phi\u1ebfu Royalty Pharma plc (RPRX)","h1_source":{"label":"H1","type":"text","formatted_value":"C\u00e1ch Mua C\u1ed5 Phi\u1ebfu Royalty Pharma plc (RPRX) - \u0110\u1ea7u T\u01b0 V\u00e0o C\u1ed5 Phi\u1ebfu Royalty Pharma plc (RPRX)"},"description":"T\u00ecm hi\u1ec3u c\u00e1ch \u0111\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Royalty Pharma plc (RPRX) v\u1edbi ph\u00e2n t\u00edch gi\u00e1 hi\u1ec7n t\u1ea1i, d\u1ef1 b\u00e1o n\u0103m 2025 v\u00e0 h\u01b0\u1edbng d\u1eabn mua t\u1eebng b\u01b0\u1edbc \u0111\u1ec3 t\u1ed1i \u0111a h\u00f3a l\u1ee3i nhu\u1eadn.","description_source":{"label":"Description","type":"textarea","formatted_value":"T\u00ecm hi\u1ec3u c\u00e1ch \u0111\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Royalty Pharma plc (RPRX) v\u1edbi ph\u00e2n t\u00edch gi\u00e1 hi\u1ec7n t\u1ea1i, d\u1ef1 b\u00e1o n\u0103m 2025 v\u00e0 h\u01b0\u1edbng d\u1eabn mua t\u1eebng b\u01b0\u1edbc \u0111\u1ec3 t\u1ed1i \u0111a h\u00f3a l\u1ee3i nhu\u1eadn."},"intro":"B\u1ea1n \u0111ang ngh\u0129 \u0111\u1ebfn vi\u1ec7c \u0111\u1ea7u t\u01b0 v\u00e0o l\u0129nh v\u1ef1c b\u1ea3n quy\u1ec1n d\u01b0\u1ee3c ph\u1ea9m? Royalty Pharma plc (RPRX) mang \u0111\u1ebfn c\u01a1 h\u1ed9i \u0111\u1ed9c \u0111\u00e1o \u0111\u1ec3 ki\u1ebfm l\u1ee3i nhu\u1eadn t\u1eeb c\u00e1c lo\u1ea1i thu\u1ed1c \u0111\u1ed9t ph\u00e1 m\u00e0 kh\u00f4ng ph\u1ea3i ch\u1ecbu r\u1ee7i ro ph\u00e1t tri\u1ec3n thu\u1ed1c truy\u1ec1n th\u1ed1ng. C\u00f4ng ty s\u00e1ng t\u1ea1o n\u00e0y s\u1edf h\u1eefu quy\u1ec1n b\u1ea3n quy\u1ec1n c\u1ee7a m\u1ed9t s\u1ed1 li\u1ec7u ph\u00e1p th\u00e0nh c\u00f4ng nh\u1ea5t th\u1ebf gi\u1edbi, t\u1ea1o ra d\u00f2ng ti\u1ec1n \u1ed5n \u0111\u1ecbnh ngay c\u1ea3 khi b\u1ea1n \u0111ang ng\u1ee7. H\u00e3y c\u00f9ng kh\u00e1m ph\u00e1 l\u00fd do t\u1ea1i sao RPRX x\u1ee9ng \u0111\u00e1ng \u0111\u01b0\u1ee3c b\u1ea1n quan t\u00e2m v\u00e0 c\u00e1ch b\u1ea1n c\u00f3 th\u1ec3 tr\u1edf th\u00e0nh c\u1ed5 \u0111\u00f4ng ngay h\u00f4m nay.","intro_source":{"label":"Intro","type":"text","formatted_value":"B\u1ea1n \u0111ang ngh\u0129 \u0111\u1ebfn vi\u1ec7c \u0111\u1ea7u t\u01b0 v\u00e0o l\u0129nh v\u1ef1c b\u1ea3n quy\u1ec1n d\u01b0\u1ee3c ph\u1ea9m? Royalty Pharma plc (RPRX) mang \u0111\u1ebfn c\u01a1 h\u1ed9i \u0111\u1ed9c \u0111\u00e1o \u0111\u1ec3 ki\u1ebfm l\u1ee3i nhu\u1eadn t\u1eeb c\u00e1c lo\u1ea1i thu\u1ed1c \u0111\u1ed9t ph\u00e1 m\u00e0 kh\u00f4ng ph\u1ea3i ch\u1ecbu r\u1ee7i ro ph\u00e1t tri\u1ec3n thu\u1ed1c truy\u1ec1n th\u1ed1ng. C\u00f4ng ty s\u00e1ng t\u1ea1o n\u00e0y s\u1edf h\u1eefu quy\u1ec1n b\u1ea3n quy\u1ec1n c\u1ee7a m\u1ed9t s\u1ed1 li\u1ec7u ph\u00e1p th\u00e0nh c\u00f4ng nh\u1ea5t th\u1ebf gi\u1edbi, t\u1ea1o ra d\u00f2ng ti\u1ec1n \u1ed5n \u0111\u1ecbnh ngay c\u1ea3 khi b\u1ea1n \u0111ang ng\u1ee7. H\u00e3y c\u00f9ng kh\u00e1m ph\u00e1 l\u00fd do t\u1ea1i sao RPRX x\u1ee9ng \u0111\u00e1ng \u0111\u01b0\u1ee3c b\u1ea1n quan t\u00e2m v\u00e0 c\u00e1ch b\u1ea1n c\u00f3 th\u1ec3 tr\u1edf th\u00e0nh c\u1ed5 \u0111\u00f4ng ngay h\u00f4m nay."},"body_html":"<h2>\ud83d\udcc8 C\u1ed5 Phi\u1ebfu Royalty Pharma: Gi\u00e1 Hi\u1ec7n T\u1ea1i v\u00e0 C\u00e1c Ng\u00e0y Quan Tr\u1ecdng<\/h2> <p>T\u00ednh \u0111\u1ebfn ng\u00e0y 28 th\u00e1ng 8 n\u0103m 2025, Royalty Pharma plc (RPRX) \u0111ang giao d\u1ecbch \u1edf m\u1ee9c <strong>35,97 USD<\/strong> tr\u00ean s\u00e0n NASDAQ. H\u00e3y \u0111\u00e1nh d\u1ea5u l\u1ecbch c\u1ee7a b\u1ea1n v\u00e0o ng\u00e0y <strong>5 th\u00e1ng 11 n\u0103m 2025<\/strong> - ng\u00e0y c\u00f4ng ty c\u00f4ng b\u1ed1 b\u00e1o c\u00e1o thu nh\u1eadp qu\u00fd 3 tr\u01b0\u1edbc khi th\u1ecb tr\u01b0\u1eddng m\u1edf c\u1eeda. L\u1ecbch s\u1eed cho th\u1ea5y c\u00e1c th\u00f4ng b\u00e1o n\u00e0y t\u1ea1o ra bi\u1ebfn \u0111\u1ed9ng gi\u00e1 \u0111\u00e1ng k\u1ec3 m\u00e0 c\u00e1c nh\u00e0 giao d\u1ecbch th\u00f4ng minh c\u00f3 th\u1ec3 t\u1eadn d\u1ee5ng.<\/p> <p><strong>C\u00e1ch B\u00e1o C\u00e1o Thu Nh\u1eadp \u1ea2nh H\u01b0\u1edfng \u0110\u1ebfn Hi\u1ec7u Su\u1ea5t C\u1ed5 Phi\u1ebfu RPRX:<\/strong><\/p> <table> <thead> <tr><th>Ng\u00e0y<\/th><th>S\u1ef1 ki\u1ec7n<\/th><th>Gi\u00e1 Tr\u01b0\u1edbc Tin<\/th><th>Thay \u0110\u1ed5i Sau Tin<\/th><\/tr> <\/thead> <tbody> <tr><td>6 th\u00e1ng 8, 2025<\/td><td>Thu nh\u1eadp qu\u00fd 2<\/td><td>37,01 USD<\/td><td>Ph\u1ea3n \u1ee9ng h\u1ed7n h\u1ee3p (EPS v\u01b0\u1ee3t, doanh thu h\u1ee5t)<\/td><\/tr> <tr><td>8 th\u00e1ng 5, 2025<\/td><td>Thu nh\u1eadp qu\u00fd 1<\/td><td>34,50 USD<\/td><td>+8% (t\u0103ng tr\u01b0\u1edfng danh m\u1ee5c m\u1ea1nh)<\/td><\/tr> <tr><td>12 th\u00e1ng 2, 2025<\/td><td>K\u1ebft qu\u1ea3 h\u00e0ng n\u0103m<\/td><td>32,80 USD<\/td><td>+12% (t\u0103ng h\u01b0\u1edbng d\u1eabn)<\/td><\/tr> <tr><td>7 th\u00e1ng 11, 2024<\/td><td>Thu nh\u1eadp qu\u00fd 3<\/td><td>29,40 USD<\/td><td>+6% (\u0111a d\u1ea1ng h\u00f3a b\u1ea3n quy\u1ec1n)<\/td><\/tr> <tr><td>8 th\u00e1ng 8, 2024<\/td><td>Thu nh\u1eadp qu\u00fd 2<\/td><td>31,20 USD<\/td><td>-4% (gi\u1ea3m t\u1ea1m th\u1eddi)<\/td><\/tr> <tr><td>9 th\u00e1ng 5, 2024<\/td><td>Thu nh\u1eadp qu\u00fd 1<\/td><td>28,90 USD<\/td><td>+8% (tin t\u1ee9c mua l\u1ea1i)<\/td><\/tr> <\/tbody> <\/table> <p><strong>Nh\u1eadn \u0110\u1ecbnh Xu H\u01b0\u1edbng:<\/strong> RPRX th\u01b0\u1eddng tr\u1ea3i qua bi\u1ebfn \u0111\u1ed9ng gi\u00e1 t\u1eeb 5-12% quanh c\u00e1c b\u00e1o c\u00e1o thu nh\u1eadp, v\u1edbi c\u00e1c b\u1ea5t ng\u1edd t\u00edch c\u1ef1c t\u1ea1o \u0111\u1ed9ng l\u1ef1c t\u0103ng b\u1ec1n v\u1eefng. K\u1ebft qu\u1ea3 qu\u00fd 2 n\u0103m 2025 g\u1ea7n \u0111\u00e2y cho th\u1ea5y b\u1ee9c tranh ph\u1ee9c t\u1ea1p - c\u00f4ng ty v\u01b0\u1ee3t \u01b0\u1edbc t\u00ednh EPS 0,04 USD nh\u01b0ng h\u1ee5t doanh thu, cho th\u1ea5y nh\u00e0 \u0111\u1ea7u t\u01b0 t\u1eadp trung nhi\u1ec1u h\u01a1n v\u00e0o t\u0103ng tr\u01b0\u1edfng b\u1ea3n quy\u1ec1n d\u00e0i h\u1ea1n thay v\u00ec bi\u1ebfn \u0111\u1ed9ng qu\u00fd.<\/p>  [cta_green text=\"B\u1eaft \u0111\u1ea7u giao d\u1ecbch\"]<h2>\ud83d\udcca H\u00e0nh Tr\u00ecnh Gi\u00e1 6 Th\u00e1ng (Th\u00e1ng 3 - Th\u00e1ng 8 N\u0103m 2025)<\/h2> <p>C\u1ed5 phi\u1ebfu Royalty Pharma \u0111\u00e3 mang l\u1ea1i l\u1ee3i nhu\u1eadn \u1ea5n t\u01b0\u1ee3ng <strong>h\u01a1n 40%<\/strong> trong s\u00e1u th\u00e1ng qua:<\/p> <p><strong>Th\u00e1ng 3 n\u0103m 2025:<\/strong> 25,54 USD (giai \u0111o\u1ea1n ph\u1ee5c h\u1ed3i sau m\u00f9a \u0111\u00f4ng)<br> <strong>Th\u00e1ng 4 n\u0103m 2025:<\/strong> 28,90 USD (d\u1ef1 \u0111o\u00e1n thu nh\u1eadp qu\u00fd 1 t\u0103ng l\u00ean)<br> <strong>Th\u00e1ng 5 n\u0103m 2025:<\/strong> 34,50 USD (k\u1ebft qu\u1ea3 qu\u00fd 1 m\u1ea1nh v\u1edbi t\u0103ng tr\u01b0\u1edfng danh m\u1ee5c 20%)<br> <strong>Th\u00e1ng 6 n\u0103m 2025:<\/strong> 36,80 USD (th\u1ecb tr\u01b0\u1eddng c\u00f4ng nh\u1eadn s\u1ee9c m\u1ea1nh m\u00f4 h\u00ecnh b\u1ea3n quy\u1ec1n)<br> <strong>Th\u00e1ng 7 n\u0103m 2025:<\/strong> 37,50 USD (giai \u0111o\u1ea1n c\u1ee7ng c\u1ed1 m\u00f9a h\u00e8)<br> <strong>Th\u00e1ng 8 n\u0103m 2025:<\/strong> 35,97 USD (m\u1ee9c hi\u1ec7n t\u1ea1i sau khi ti\u00eau h\u00f3a k\u1ebft qu\u1ea3 qu\u00fd 2)<\/p> <p>Hi\u1ec7u su\u1ea5t \u0111\u00e1ng ch\u00fa \u00fd n\u00e0y xu\u1ea5t ph\u00e1t t\u1eeb m\u1ed9t s\u1ed1 y\u1ebfu t\u1ed1 ch\u00ednh:<\/p> <ul> <li><strong>Doanh thu danh m\u1ee5c t\u0103ng 20% so v\u1edbi c\u00f9ng k\u1ef3 n\u0103m tr\u01b0\u1edbc<\/strong> \u0111\u1ea1t 727 tri\u1ec7u USD trong qu\u00fd 2<\/li> <li><strong>Chi\u1ebfn l\u01b0\u1ee3c \u0111a d\u1ea1ng h\u00f3a b\u1ea3n quy\u1ec1n<\/strong> t\u1ea1o ni\u1ec1m tin cho nh\u00e0 \u0111\u1ea7u t\u01b0<\/li> <li><strong>Ho\u00e0n th\u00e0nh giao d\u1ecbch n\u1ed9i b\u1ed9 h\u00f3a<\/strong> gi\u1ea3m chi ph\u00ed v\u1eadn h\u00e0nh t\u1eeb 10% xu\u1ed1ng c\u00f2n 9-9,5%<\/li> <li><strong>V\u1ecb th\u1ebf ti\u1ec1n m\u1eb7t m\u1ea1nh<\/strong> cho ph\u00e9p c\u00e1c th\u01b0\u01a1ng v\u1ee5 mua l\u1ea1i chi\u1ebfn l\u01b0\u1ee3c nh\u01b0 th\u01b0\u01a1ng v\u1ee5 Imdelltra tr\u1ecb gi\u00e1 885 tri\u1ec7u USD<\/li> <\/ul>  <h2>\ud83d\udd2e D\u1ef1 B\u00e1o Gi\u00e1: Tri\u1ec3n V\u1ecdng 2025-2030<\/h2> <p><strong>M\u1ee5c ti\u00eau cu\u1ed1i n\u0103m 2025:<\/strong> 42-46 USD (d\u1ef1a tr\u00ean \u0111\u1ed3ng thu\u1eadn nh\u00e0 ph\u00e2n t\u00edch hi\u1ec7n t\u1ea1i 45,33 USD, t\u01b0\u01a1ng \u1ee9ng ti\u1ec1m n\u0103ng t\u0103ng 25,99%) \u2192 <strong>MUA M\u1ea0NH<\/strong><\/p> <p><strong>D\u1ef1 b\u00e1o n\u0103m 2026:<\/strong> 48-54 USD (m\u00f4 h\u00ecnh b\u1ea3n quy\u1ec1n tr\u01b0\u1edfng th\u00e0nh v\u00e0 c\u00e1c th\u01b0\u01a1ng v\u1ee5 mua l\u1ea1i m\u1edbi)<br> <strong>D\u1ef1 b\u00e1o n\u0103m 2028:<\/strong> 58-65 USD (t\u0103ng tr\u01b0\u1edfng b\u1ea3n quy\u1ec1n b\u1ec1n v\u1eefng v\u00e0 m\u1edf r\u1ed9ng th\u1ecb tr\u01b0\u1eddng)<br> <strong>T\u1ea7m nh\u00ecn n\u0103m 2030:<\/strong> 70-80 USD (v\u1ecb th\u1ebf d\u1eabn \u0111\u1ea7u ng\u00e0nh v\u00e0 xu h\u01b0\u1edbng ch\u0103m s\u00f3c s\u1ee9c kh\u1ecfe to\u00e0n c\u1ea7u)<\/p> <p>Tri\u1ec3n v\u1ecdng t\u00edch c\u1ef1c \u0111\u01b0\u1ee3c h\u1ed7 tr\u1ee3 b\u1edfi m\u00f4 h\u00ecnh kinh doanh \u0111\u1ed9c \u0111\u00e1o c\u1ee7a Royalty Pharma - h\u1ecd ki\u1ebfm l\u1ee3i t\u1eeb c\u00e1c lo\u1ea1i thu\u1ed1c th\u00e0nh c\u00f4ng m\u00e0 kh\u00f4ng ch\u1ecbu r\u1ee7i ro ph\u00e1t tri\u1ec3n. V\u1edbi h\u01a1n 35 li\u1ec7u ph\u00e1p th\u01b0\u01a1ng m\u1ea1i v\u00e0 14 \u1ee9ng vi\u00ean \u0111ang trong giai \u0111o\u1ea1n ph\u00e1t tri\u1ec3n, c\u00f4ng ty c\u00f3 nhi\u1ec1u ngu\u1ed3n doanh thu cung c\u1ea5p s\u1ef1 \u1ed5n \u0111\u1ecbnh trong th\u1eddi k\u1ef3 bi\u1ebfn \u0111\u1ed9ng th\u1ecb tr\u01b0\u1eddng.<\/p>  <h2>\u26a0\ufe0f R\u1ee7i Ro Ch\u00ednh v\u00e0 T\u00edn Hi\u1ec7u T\u00edch C\u1ef1c<\/h2> <p><strong>R\u1ee7i ro c\u1ea7n xem x\u00e9t:<\/strong><\/p> <ul> <li><strong>G\u00e1nh n\u1ee3 7,8 t\u1ef7 USD<\/strong> t\u1ea1o ra ngh\u0129a v\u1ee5 l\u00e3i su\u1ea5t 275 tri\u1ec7u USD m\u1ed7i n\u0103m<\/li> <li><strong>\u0110e d\u1ecda c\u1ea1nh tranh t\u1eeb thu\u1ed1c generic<\/strong> cho c\u00e1c s\u1ea3n ph\u1ea9m ch\u1ee7 ch\u1ed1t nh\u01b0 Promacta<\/li> <li><strong>Kh\u00f4ng ch\u1eafc ch\u1eafn v\u1ec1 quy \u0111\u1ecbnh<\/strong> li\u00ean quan \u0111\u1ebfn ch\u00ednh s\u00e1ch gi\u00e1 thu\u1ed1c (k\u1ebft qu\u1ea3 MFN)<\/li> <li><strong>Th\u00e1ch th\u1ee9c ph\u00e2n b\u1ed5 v\u1ed1n<\/strong> v\u1edbi ch\u01b0\u01a1ng tr\u00ecnh mua l\u1ea1i c\u1ed5 phi\u1ebfu m\u1ea1nh tay tr\u1ecb gi\u00e1 3 t\u1ef7 USD<\/li> <\/ul> <p><strong>T\u00edn hi\u1ec7u t\u00edch c\u1ef1c cho n\u0103m 2025:<\/strong><\/p> <ul> <li><strong>Th\u01b0\u01a1ng v\u1ee5 mua l\u1ea1i 885 tri\u1ec7u USD g\u1ea7n \u0111\u00e2y<\/strong> quy\u1ec1n b\u1ea3n quy\u1ec1n Imdelltra (<a href=\"https:\/\/www.royaltypharma.com\/news\/royalty-pharma-reports-second-quarter-2025-results\/\">K\u1ebft qu\u1ea3 qu\u00fd 2 n\u0103m 2025<\/a>)<\/li> <li><strong>T\u0103ng tr\u01b0\u1edfng doanh thu danh m\u1ee5c 20%<\/strong> so v\u1edbi c\u00f9ng k\u1ef3 n\u0103m tr\u01b0\u1edbc<\/li> <li><strong>\u0110\u1ecbnh m\u1ee9c c\u1ed5 t\u1ee9c 2,39-2,45%<\/strong> v\u1edbi c\u00e1c kho\u1ea3n thanh to\u00e1n qu\u00fd \u0111\u1ec1u \u0111\u1eb7n<\/li> <li><strong>H\u1ed3 s\u01a1 bi\u1ebfn \u0111\u1ed9ng th\u1ea5p<\/strong> (beta 0,54) so v\u1edbi ng\u00e0nh c\u00f4ng ngh\u1ec7 sinh h\u1ecdc<\/li> <li><strong>Ho\u00e0n th\u00e0nh n\u1ed9i b\u1ed9 h\u00f3a<\/strong> gi\u1ea3m \u0111\u00e1ng k\u1ec3 chi ph\u00ed v\u1eadn h\u00e0nh<\/li> <\/ul>  <h2>\ud83d\udee1\ufe0f Nh\u00e0 Giao D\u1ecbch M\u1edbi N\u00ean L\u00e0m G\u00ec H\u00f4m Nay?<\/h2> <ol> <li><strong>B\u1eaft \u0111\u1ea7u nh\u1ecf v\u1edbi ph\u01b0\u01a1ng ph\u00e1p trung b\u00ecnh gi\u00e1 theo \u0111\u00f4 la<\/strong> - \u0111\u1ea7u t\u01b0 s\u1ed1 ti\u1ec1n c\u1ed1 \u0111\u1ecbnh h\u00e0ng tu\u1ea7n \u0111\u1ec3 tr\u00e1nh sai l\u1ea7m v\u1ec1 th\u1eddi \u0111i\u1ec3m<\/li> <li><strong>\u0110\u1eb7t c\u1ea3nh b\u00e1o gi\u00e1 quanh m\u1ee9c 34-36 USD<\/strong> \u0111\u1ec3 c\u00f3 \u0111i\u1ec3m v\u00e0o h\u1ea5p d\u1eabn tr\u01b0\u1edbc b\u00e1o c\u00e1o thu nh\u1eadp th\u00e1ng 11<\/li> <li><strong>Ch\u1ec9 ph\u00e2n b\u1ed5 5-10% danh m\u1ee5c<\/strong> cho RPRX \u0111\u1ec3 \u0111a d\u1ea1ng h\u00f3a h\u1ee3p l\u00fd<\/li> <li><strong>Theo d\u00f5i s\u00e1t b\u00e1o c\u00e1o thu nh\u1eadp ng\u00e0y 5 th\u00e1ng 11<\/strong> - l\u1ecbch s\u1eed cho th\u1ea5y \u0111\u00e2y l\u00e0 c\u01a1 h\u1ed9i mua t\u1ed1t nh\u1ea5t<\/li> <\/ol> <p>Ch\u00e2m ng\u00f4n h\u00e0i h\u01b0\u1edbc d\u00e0nh cho nh\u00e0 giao d\u1ecbch: \"Giao d\u1ecbch RPRX gi\u1ed1ng nh\u01b0 thu ti\u1ec1n b\u1ea3n quy\u1ec1n - b\u1ea1n mu\u1ed1n c\u00e1c hit ti\u1ebfp t\u1ee5c \u0111\u1ebfn trong khi t\u1eadn h\u01b0\u1edfng thu nh\u1eadp \u1ed5n \u0111\u1ecbnh. Ch\u1ec9 \u0111\u1eebng mong m\u1ed7i qu\u00fd \u0111\u1ec1u l\u00e0 m\u1ed9t b\u1ea3n hit \u0111\u1ee9ng \u0111\u1ea7u b\u1ea3ng x\u1ebfp h\u1ea1ng!\"<\/p>  <h2>\u2705 C\u00e1ch Mua C\u1ed5 Phi\u1ebfu Royalty Pharma plc (RPRX) - T\u1eebng B\u01b0\u1edbc<\/h2> <table> <thead> <tr><th>B\u01b0\u1edbc<\/th><th>H\u00e0nh \u0110\u1ed9ng<\/th><th>T\u1ea1i Sao Quan Tr\u1ecdng<\/th><\/tr> <\/thead> <tbody> <tr><td>1<\/td><td>Ch\u1ecdn n\u1ec1n t\u1ea3ng giao d\u1ecbch<\/td><td>\u0110\u1ea3m b\u1ea3o n\u1ec1n t\u1ea3ng c\u00f3 truy c\u1eadp NASDAQ v\u00e0 ph\u00ed h\u1ee3p l\u00fd<\/td><\/tr> <tr><td>2<\/td><td>Ho\u00e0n th\u00e0nh x\u00e1c minh t\u00e0i kho\u1ea3n<\/td><td>Th\u00f4ng th\u01b0\u1eddng y\u00eau c\u1ea7u gi\u1ea5y t\u1edd t\u00f9y th\u00e2n v\u00e0 b\u1eb1ng ch\u1ee9ng \u0111\u1ecba ch\u1ec9<\/td><\/tr> <tr><td>3<\/td><td>N\u1ea1p ti\u1ec1n<\/td><td>B\u1eaft \u0111\u1ea7u v\u1edbi s\u1ed1 ti\u1ec1n b\u1ea1n c\u1ea3m th\u1ea5y tho\u1ea3i m\u00e1i khi r\u1ee7i ro<\/td><\/tr> <tr><td>4<\/td><td>T\u00ecm ki\u1ebfm \"RPRX\"<\/td><td>S\u1eed d\u1ee5ng m\u00e3 ch\u1ee9ng kho\u00e1n ch\u00ednh x\u00e1c \u0111\u1ec3 \u0111\u1ea3m b\u1ea3o \u0111\u1ed9 ch\u00ednh x\u00e1c<\/td><\/tr> <tr><td>5<\/td><td>Ch\u1ecdn lo\u1ea1i l\u1ec7nh<\/td><td>D\u00f9ng l\u1ec7nh gi\u1edbi h\u1ea1n \u0111\u1ec3 ki\u1ec3m so\u00e1t gi\u00e1 v\u00e0o<\/td><\/tr> <tr><td>6<\/td><td>Xem l\u1ea1i v\u00e0 x\u00e1c nh\u1eadn<\/td><td>Ki\u1ec3m tra m\u1ee9c ph\u00ed hoa h\u1ed3ng tr\u01b0\u1edbc khi ho\u00e0n t\u1ea5t<\/td><\/tr> <tr><td>7<\/td><td>Gi\u00e1m s\u00e1t v\u1ecb th\u1ebf<\/td><td>\u0110\u1eb7t c\u1ea3nh b\u00e1o cho m\u1ee5c ti\u00eau gi\u00e1 v\u00e0 \u0111i\u1ec3m d\u1eebng l\u1ed7<\/td><\/tr> <\/tbody> <\/table>  <h2>\ud83d\udca1 T\u1ea1i Sao Pocket Option Ph\u00f9 H\u1ee3p V\u1edbi Nh\u00e0 \u0110\u1ea7u T\u01b0 M\u1edbi<\/h2> <p>\u0110\u1ed1i v\u1edbi nh\u1eefng ng\u01b0\u1eddi m\u1edbi b\u1eaft \u0111\u1ea7u h\u00e0nh tr\u00ecnh \u0111\u1ea7u t\u01b0, Pocket Option mang l\u1ea1i nh\u1eefng l\u1ee3i th\u1ebf v\u01b0\u1ee3t tr\u1ed9i:<\/p> <ul> <li><strong>S\u1ed1 ti\u1ec1n n\u1ea1p t\u1ed1i thi\u1ec3u ch\u1ec9 5 USD<\/strong> - ho\u00e0n h\u1ea3o \u0111\u1ec3 th\u1eed nghi\u1ec7m chi\u1ebfn l\u01b0\u1ee3c v\u1edbi r\u1ee7i ro th\u1ea5p<\/li> <li><strong>Quy tr\u00ecnh KYC nhanh nh\u01b0 ch\u1edbp<\/strong> - x\u00e1c minh ch\u1ec9 v\u1edbi m\u1ed9t gi\u1ea5y t\u1edd trong v\u00e0i ph\u00fat<\/li> <li><strong>H\u00e0ng tr\u0103m ph\u01b0\u01a1ng th\u1ee9c r\u00fat ti\u1ec1n<\/strong> - t\u1eeb ti\u1ec1n \u0111i\u1ec7n t\u1eed \u0111\u1ebfn ng\u00e2n h\u00e0ng truy\u1ec1n th\u1ed1ng<\/li> <li><strong:Giao di\u1ec7n th\u00e2n thi\u1ec7n v\u1edbi ng\u01b0\u1eddi d\u00f9ng<\/strong> - thi\u1ebft k\u1ebf \u0111\u1eb7c bi\u1ec7t cho ng\u01b0\u1eddi m\u1edbi h\u1ecdc th\u1ecb tr\u01b0\u1eddng<\/li> <\/ul> <p>R\u00e0o c\u1ea3n gia nh\u1eadp th\u1ea5p c\u1ee7a n\u1ec1n t\u1ea3ng l\u00e0m cho n\u00f3 l\u00fd t\u01b0\u1edfng cho nh\u00e0 \u0111\u1ea7u t\u01b0 mu\u1ed1n x\u00e2y d\u1ef1ng v\u1ecb th\u1ebf t\u1ea1i c\u00e1c c\u00f4ng ty nh\u01b0 Royalty Pharma m\u1ed9t c\u00e1ch t\u1eeb t\u1eeb trong khi h\u1ecdc h\u1ecfi v\u1ec1 \u0111\u1ed9ng l\u1ef1c th\u1ecb tr\u01b0\u1eddng.<\/p>  <h2>\ud83c\udf0d Royalty Pharma N\u0103m 2025: G\u00e3 Kh\u1ed5ng L\u1ed3 Im L\u1eb7ng Trong T\u00e0i Ch\u00ednh Ch\u0103m S\u00f3c S\u1ee9c Kh\u1ecfe<\/h2> <p>Royalty Pharma \u0111\u00e3 c\u00e1ch m\u1ea1ng h\u00f3a c\u00e1ch nh\u00e0 \u0111\u1ea7u t\u01b0 tham gia v\u00e0o \u0111\u1ed5i m\u1edbi d\u01b0\u1ee3c ph\u1ea9m. Thay v\u00ec \u0111\u1eb7t c\u01b0\u1ee3c v\u00e0o ph\u00e1t tri\u1ec3n thu\u1ed1c c\u00e1 nh\u00e2n, c\u00f4ng ty mua quy\u1ec1n b\u1ea3n quy\u1ec1n c\u00e1c li\u1ec7u ph\u00e1p th\u00e0nh c\u00f4ng, t\u1ea1o ra d\u00f2ng thu nh\u1eadp \u0111a d\u1ea1ng t\u1eeb c\u00e1c lo\u1ea1i thu\u1ed1c bom t\u1ea5n tr\u00ean nhi\u1ec1u l\u0129nh v\u1ef1c \u0111i\u1ec1u tr\u1ecb.<\/p> <p>C\u00f4ng ty hi\u1ec7n n\u1eafm quy\u1ec1n \u0111\u1ed1i v\u1edbi h\u01a1n 35 s\u1ea3n ph\u1ea9m th\u01b0\u01a1ng m\u1ea1i bao g\u1ed3m \u0111i\u1ec1u tr\u1ecb ung th\u01b0, b\u1ec7nh hi\u1ebfm v\u00e0 c\u00e1c b\u1ec7nh m\u00e3n t\u00ednh. Th\u01b0\u01a1ng v\u1ee5 mua l\u1ea1i quy\u1ec1n Imdelltra tr\u1ecb gi\u00e1 885 tri\u1ec7u USD g\u1ea7n \u0111\u00e2y - m\u1ed9t li\u1ec7u ph\u00e1p mi\u1ec5n d\u1ecbch \u0111\u1ed9t ph\u00e1 cho ung th\u01b0 ph\u1ed5i t\u1ebf b\u00e0o nh\u1ecf - th\u1ec3 hi\u1ec7n s\u1ef1 t\u1eadp trung chi\u1ebfn l\u01b0\u1ee3c v\u00e0o c\u00e1c lo\u1ea1i thu\u1ed1c chuy\u1ec3n \u0111\u1ed5i.<\/p> <p><strong>S\u1ef1 th\u1eadt th\u00fa v\u1ecb n\u0103m 2025:<\/strong> Danh m\u1ee5c c\u1ee7a Royalty Pharma bao g\u1ed3m b\u1ea3n quy\u1ec1n t\u1eeb c\u00e1c lo\u1ea1i thu\u1ed1c \u0111i\u1ec1u tr\u1ecb kho\u1ea3ng 1 trong 100 b\u1ec7nh nh\u00e2n tr\u00ean to\u00e0n c\u1ea7u. M\u00f4 h\u00ecnh doanh thu c\u1ee7a h\u1ecd th\u1ef1c ch\u1ea5t bi\u1ebfn h\u1ecd th\u00e0nh \u0111\u1ed1i t\u00e1c trong \u0111\u1ed5i m\u1edbi ch\u0103m s\u00f3c s\u1ee9c kh\u1ecfe m\u00e0 kh\u00f4ng ch\u1ecbu r\u1ee7i ro c\u00f4ng ngh\u1ec7 sinh h\u1ecdc truy\u1ec1n th\u1ed1ng!<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>\ud83d\udcc8 C\u1ed5 Phi\u1ebfu Royalty Pharma: Gi\u00e1 Hi\u1ec7n T\u1ea1i v\u00e0 C\u00e1c Ng\u00e0y Quan Tr\u1ecdng<\/h2>\n<p>T\u00ednh \u0111\u1ebfn ng\u00e0y 28 th\u00e1ng 8 n\u0103m 2025, Royalty Pharma plc (RPRX) \u0111ang giao d\u1ecbch \u1edf m\u1ee9c <strong>35,97 USD<\/strong> tr\u00ean s\u00e0n NASDAQ. H\u00e3y \u0111\u00e1nh d\u1ea5u l\u1ecbch c\u1ee7a b\u1ea1n v\u00e0o ng\u00e0y <strong>5 th\u00e1ng 11 n\u0103m 2025<\/strong> &#8211; ng\u00e0y c\u00f4ng ty c\u00f4ng b\u1ed1 b\u00e1o c\u00e1o thu nh\u1eadp qu\u00fd 3 tr\u01b0\u1edbc khi th\u1ecb tr\u01b0\u1eddng m\u1edf c\u1eeda. L\u1ecbch s\u1eed cho th\u1ea5y c\u00e1c th\u00f4ng b\u00e1o n\u00e0y t\u1ea1o ra bi\u1ebfn \u0111\u1ed9ng gi\u00e1 \u0111\u00e1ng k\u1ec3 m\u00e0 c\u00e1c nh\u00e0 giao d\u1ecbch th\u00f4ng minh c\u00f3 th\u1ec3 t\u1eadn d\u1ee5ng.<\/p>\n<p><strong>C\u00e1ch B\u00e1o C\u00e1o Thu Nh\u1eadp \u1ea2nh H\u01b0\u1edfng \u0110\u1ebfn Hi\u1ec7u Su\u1ea5t C\u1ed5 Phi\u1ebfu RPRX:<\/strong><\/p>\n<table>\n<thead>\n<tr>\n<th>Ng\u00e0y<\/th>\n<th>S\u1ef1 ki\u1ec7n<\/th>\n<th>Gi\u00e1 Tr\u01b0\u1edbc Tin<\/th>\n<th>Thay \u0110\u1ed5i Sau Tin<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>6 th\u00e1ng 8, 2025<\/td>\n<td>Thu nh\u1eadp qu\u00fd 2<\/td>\n<td>37,01 USD<\/td>\n<td>Ph\u1ea3n \u1ee9ng h\u1ed7n h\u1ee3p (EPS v\u01b0\u1ee3t, doanh thu h\u1ee5t)<\/td>\n<\/tr>\n<tr>\n<td>8 th\u00e1ng 5, 2025<\/td>\n<td>Thu nh\u1eadp qu\u00fd 1<\/td>\n<td>34,50 USD<\/td>\n<td>+8% (t\u0103ng tr\u01b0\u1edfng danh m\u1ee5c m\u1ea1nh)<\/td>\n<\/tr>\n<tr>\n<td>12 th\u00e1ng 2, 2025<\/td>\n<td>K\u1ebft qu\u1ea3 h\u00e0ng n\u0103m<\/td>\n<td>32,80 USD<\/td>\n<td>+12% (t\u0103ng h\u01b0\u1edbng d\u1eabn)<\/td>\n<\/tr>\n<tr>\n<td>7 th\u00e1ng 11, 2024<\/td>\n<td>Thu nh\u1eadp qu\u00fd 3<\/td>\n<td>29,40 USD<\/td>\n<td>+6% (\u0111a d\u1ea1ng h\u00f3a b\u1ea3n quy\u1ec1n)<\/td>\n<\/tr>\n<tr>\n<td>8 th\u00e1ng 8, 2024<\/td>\n<td>Thu nh\u1eadp qu\u00fd 2<\/td>\n<td>31,20 USD<\/td>\n<td>-4% (gi\u1ea3m t\u1ea1m th\u1eddi)<\/td>\n<\/tr>\n<tr>\n<td>9 th\u00e1ng 5, 2024<\/td>\n<td>Thu nh\u1eadp qu\u00fd 1<\/td>\n<td>28,90 USD<\/td>\n<td>+8% (tin t\u1ee9c mua l\u1ea1i)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><strong>Nh\u1eadn \u0110\u1ecbnh Xu H\u01b0\u1edbng:<\/strong> RPRX th\u01b0\u1eddng tr\u1ea3i qua bi\u1ebfn \u0111\u1ed9ng gi\u00e1 t\u1eeb 5-12% quanh c\u00e1c b\u00e1o c\u00e1o thu nh\u1eadp, v\u1edbi c\u00e1c b\u1ea5t ng\u1edd t\u00edch c\u1ef1c t\u1ea1o \u0111\u1ed9ng l\u1ef1c t\u0103ng b\u1ec1n v\u1eefng. K\u1ebft qu\u1ea3 qu\u00fd 2 n\u0103m 2025 g\u1ea7n \u0111\u00e2y cho th\u1ea5y b\u1ee9c tranh ph\u1ee9c t\u1ea1p &#8211; c\u00f4ng ty v\u01b0\u1ee3t \u01b0\u1edbc t\u00ednh EPS 0,04 USD nh\u01b0ng h\u1ee5t doanh thu, cho th\u1ea5y nh\u00e0 \u0111\u1ea7u t\u01b0 t\u1eadp trung nhi\u1ec1u h\u01a1n v\u00e0o t\u0103ng tr\u01b0\u1edfng b\u1ea3n quy\u1ec1n d\u00e0i h\u1ea1n thay v\u00ec bi\u1ebfn \u0111\u1ed9ng qu\u00fd.<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/vt\/register\/\" class=\"po-cta-green\">B\u1eaft \u0111\u1ea7u giao d\u1ecbch\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>\ud83d\udcca H\u00e0nh Tr\u00ecnh Gi\u00e1 6 Th\u00e1ng (Th\u00e1ng 3 &#8211; Th\u00e1ng 8 N\u0103m 2025)<\/h2>\n<p>C\u1ed5 phi\u1ebfu Royalty Pharma \u0111\u00e3 mang l\u1ea1i l\u1ee3i nhu\u1eadn \u1ea5n t\u01b0\u1ee3ng <strong>h\u01a1n 40%<\/strong> trong s\u00e1u th\u00e1ng qua:<\/p>\n<p><strong>Th\u00e1ng 3 n\u0103m 2025:<\/strong> 25,54 USD (giai \u0111o\u1ea1n ph\u1ee5c h\u1ed3i sau m\u00f9a \u0111\u00f4ng)<br \/> <strong>Th\u00e1ng 4 n\u0103m 2025:<\/strong> 28,90 USD (d\u1ef1 \u0111o\u00e1n thu nh\u1eadp qu\u00fd 1 t\u0103ng l\u00ean)<br \/> <strong>Th\u00e1ng 5 n\u0103m 2025:<\/strong> 34,50 USD (k\u1ebft qu\u1ea3 qu\u00fd 1 m\u1ea1nh v\u1edbi t\u0103ng tr\u01b0\u1edfng danh m\u1ee5c 20%)<br \/> <strong>Th\u00e1ng 6 n\u0103m 2025:<\/strong> 36,80 USD (th\u1ecb tr\u01b0\u1eddng c\u00f4ng nh\u1eadn s\u1ee9c m\u1ea1nh m\u00f4 h\u00ecnh b\u1ea3n quy\u1ec1n)<br \/> <strong>Th\u00e1ng 7 n\u0103m 2025:<\/strong> 37,50 USD (giai \u0111o\u1ea1n c\u1ee7ng c\u1ed1 m\u00f9a h\u00e8)<br \/> <strong>Th\u00e1ng 8 n\u0103m 2025:<\/strong> 35,97 USD (m\u1ee9c hi\u1ec7n t\u1ea1i sau khi ti\u00eau h\u00f3a k\u1ebft qu\u1ea3 qu\u00fd 2)<\/p>\n<p>Hi\u1ec7u su\u1ea5t \u0111\u00e1ng ch\u00fa \u00fd n\u00e0y xu\u1ea5t ph\u00e1t t\u1eeb m\u1ed9t s\u1ed1 y\u1ebfu t\u1ed1 ch\u00ednh:<\/p>\n<ul>\n<li><strong>Doanh thu danh m\u1ee5c t\u0103ng 20% so v\u1edbi c\u00f9ng k\u1ef3 n\u0103m tr\u01b0\u1edbc<\/strong> \u0111\u1ea1t 727 tri\u1ec7u USD trong qu\u00fd 2<\/li>\n<li><strong>Chi\u1ebfn l\u01b0\u1ee3c \u0111a d\u1ea1ng h\u00f3a b\u1ea3n quy\u1ec1n<\/strong> t\u1ea1o ni\u1ec1m tin cho nh\u00e0 \u0111\u1ea7u t\u01b0<\/li>\n<li><strong>Ho\u00e0n th\u00e0nh giao d\u1ecbch n\u1ed9i b\u1ed9 h\u00f3a<\/strong> gi\u1ea3m chi ph\u00ed v\u1eadn h\u00e0nh t\u1eeb 10% xu\u1ed1ng c\u00f2n 9-9,5%<\/li>\n<li><strong>V\u1ecb th\u1ebf ti\u1ec1n m\u1eb7t m\u1ea1nh<\/strong> cho ph\u00e9p c\u00e1c th\u01b0\u01a1ng v\u1ee5 mua l\u1ea1i chi\u1ebfn l\u01b0\u1ee3c nh\u01b0 th\u01b0\u01a1ng v\u1ee5 Imdelltra tr\u1ecb gi\u00e1 885 tri\u1ec7u USD<\/li>\n<\/ul>\n<h2>\ud83d\udd2e D\u1ef1 B\u00e1o Gi\u00e1: Tri\u1ec3n V\u1ecdng 2025-2030<\/h2>\n<p><strong>M\u1ee5c ti\u00eau cu\u1ed1i n\u0103m 2025:<\/strong> 42-46 USD (d\u1ef1a tr\u00ean \u0111\u1ed3ng thu\u1eadn nh\u00e0 ph\u00e2n t\u00edch hi\u1ec7n t\u1ea1i 45,33 USD, t\u01b0\u01a1ng \u1ee9ng ti\u1ec1m n\u0103ng t\u0103ng 25,99%) \u2192 <strong>MUA M\u1ea0NH<\/strong><\/p>\n<p><strong>D\u1ef1 b\u00e1o n\u0103m 2026:<\/strong> 48-54 USD (m\u00f4 h\u00ecnh b\u1ea3n quy\u1ec1n tr\u01b0\u1edfng th\u00e0nh v\u00e0 c\u00e1c th\u01b0\u01a1ng v\u1ee5 mua l\u1ea1i m\u1edbi)<br \/> <strong>D\u1ef1 b\u00e1o n\u0103m 2028:<\/strong> 58-65 USD (t\u0103ng tr\u01b0\u1edfng b\u1ea3n quy\u1ec1n b\u1ec1n v\u1eefng v\u00e0 m\u1edf r\u1ed9ng th\u1ecb tr\u01b0\u1eddng)<br \/> <strong>T\u1ea7m nh\u00ecn n\u0103m 2030:<\/strong> 70-80 USD (v\u1ecb th\u1ebf d\u1eabn \u0111\u1ea7u ng\u00e0nh v\u00e0 xu h\u01b0\u1edbng ch\u0103m s\u00f3c s\u1ee9c kh\u1ecfe to\u00e0n c\u1ea7u)<\/p>\n<p>Tri\u1ec3n v\u1ecdng t\u00edch c\u1ef1c \u0111\u01b0\u1ee3c h\u1ed7 tr\u1ee3 b\u1edfi m\u00f4 h\u00ecnh kinh doanh \u0111\u1ed9c \u0111\u00e1o c\u1ee7a Royalty Pharma &#8211; h\u1ecd ki\u1ebfm l\u1ee3i t\u1eeb c\u00e1c lo\u1ea1i thu\u1ed1c th\u00e0nh c\u00f4ng m\u00e0 kh\u00f4ng ch\u1ecbu r\u1ee7i ro ph\u00e1t tri\u1ec3n. V\u1edbi h\u01a1n 35 li\u1ec7u ph\u00e1p th\u01b0\u01a1ng m\u1ea1i v\u00e0 14 \u1ee9ng vi\u00ean \u0111ang trong giai \u0111o\u1ea1n ph\u00e1t tri\u1ec3n, c\u00f4ng ty c\u00f3 nhi\u1ec1u ngu\u1ed3n doanh thu cung c\u1ea5p s\u1ef1 \u1ed5n \u0111\u1ecbnh trong th\u1eddi k\u1ef3 bi\u1ebfn \u0111\u1ed9ng th\u1ecb tr\u01b0\u1eddng.<\/p>\n<h2>\u26a0\ufe0f R\u1ee7i Ro Ch\u00ednh v\u00e0 T\u00edn Hi\u1ec7u T\u00edch C\u1ef1c<\/h2>\n<p><strong>R\u1ee7i ro c\u1ea7n xem x\u00e9t:<\/strong><\/p>\n<ul>\n<li><strong>G\u00e1nh n\u1ee3 7,8 t\u1ef7 USD<\/strong> t\u1ea1o ra ngh\u0129a v\u1ee5 l\u00e3i su\u1ea5t 275 tri\u1ec7u USD m\u1ed7i n\u0103m<\/li>\n<li><strong>\u0110e d\u1ecda c\u1ea1nh tranh t\u1eeb thu\u1ed1c generic<\/strong> cho c\u00e1c s\u1ea3n ph\u1ea9m ch\u1ee7 ch\u1ed1t nh\u01b0 Promacta<\/li>\n<li><strong>Kh\u00f4ng ch\u1eafc ch\u1eafn v\u1ec1 quy \u0111\u1ecbnh<\/strong> li\u00ean quan \u0111\u1ebfn ch\u00ednh s\u00e1ch gi\u00e1 thu\u1ed1c (k\u1ebft qu\u1ea3 MFN)<\/li>\n<li><strong>Th\u00e1ch th\u1ee9c ph\u00e2n b\u1ed5 v\u1ed1n<\/strong> v\u1edbi ch\u01b0\u01a1ng tr\u00ecnh mua l\u1ea1i c\u1ed5 phi\u1ebfu m\u1ea1nh tay tr\u1ecb gi\u00e1 3 t\u1ef7 USD<\/li>\n<\/ul>\n<p><strong>T\u00edn hi\u1ec7u t\u00edch c\u1ef1c cho n\u0103m 2025:<\/strong><\/p>\n<ul>\n<li><strong>Th\u01b0\u01a1ng v\u1ee5 mua l\u1ea1i 885 tri\u1ec7u USD g\u1ea7n \u0111\u00e2y<\/strong> quy\u1ec1n b\u1ea3n quy\u1ec1n Imdelltra (<a href=\"https:\/\/www.royaltypharma.com\/news\/royalty-pharma-reports-second-quarter-2025-results\/\">K\u1ebft qu\u1ea3 qu\u00fd 2 n\u0103m 2025<\/a>)<\/li>\n<li><strong>T\u0103ng tr\u01b0\u1edfng doanh thu danh m\u1ee5c 20%<\/strong> so v\u1edbi c\u00f9ng k\u1ef3 n\u0103m tr\u01b0\u1edbc<\/li>\n<li><strong>\u0110\u1ecbnh m\u1ee9c c\u1ed5 t\u1ee9c 2,39-2,45%<\/strong> v\u1edbi c\u00e1c kho\u1ea3n thanh to\u00e1n qu\u00fd \u0111\u1ec1u \u0111\u1eb7n<\/li>\n<li><strong>H\u1ed3 s\u01a1 bi\u1ebfn \u0111\u1ed9ng th\u1ea5p<\/strong> (beta 0,54) so v\u1edbi ng\u00e0nh c\u00f4ng ngh\u1ec7 sinh h\u1ecdc<\/li>\n<li><strong>Ho\u00e0n th\u00e0nh n\u1ed9i b\u1ed9 h\u00f3a<\/strong> gi\u1ea3m \u0111\u00e1ng k\u1ec3 chi ph\u00ed v\u1eadn h\u00e0nh<\/li>\n<\/ul>\n<h2>\ud83d\udee1\ufe0f Nh\u00e0 Giao D\u1ecbch M\u1edbi N\u00ean L\u00e0m G\u00ec H\u00f4m Nay?<\/h2>\n<ol>\n<li><strong>B\u1eaft \u0111\u1ea7u nh\u1ecf v\u1edbi ph\u01b0\u01a1ng ph\u00e1p trung b\u00ecnh gi\u00e1 theo \u0111\u00f4 la<\/strong> &#8211; \u0111\u1ea7u t\u01b0 s\u1ed1 ti\u1ec1n c\u1ed1 \u0111\u1ecbnh h\u00e0ng tu\u1ea7n \u0111\u1ec3 tr\u00e1nh sai l\u1ea7m v\u1ec1 th\u1eddi \u0111i\u1ec3m<\/li>\n<li><strong>\u0110\u1eb7t c\u1ea3nh b\u00e1o gi\u00e1 quanh m\u1ee9c 34-36 USD<\/strong> \u0111\u1ec3 c\u00f3 \u0111i\u1ec3m v\u00e0o h\u1ea5p d\u1eabn tr\u01b0\u1edbc b\u00e1o c\u00e1o thu nh\u1eadp th\u00e1ng 11<\/li>\n<li><strong>Ch\u1ec9 ph\u00e2n b\u1ed5 5-10% danh m\u1ee5c<\/strong> cho RPRX \u0111\u1ec3 \u0111a d\u1ea1ng h\u00f3a h\u1ee3p l\u00fd<\/li>\n<li><strong>Theo d\u00f5i s\u00e1t b\u00e1o c\u00e1o thu nh\u1eadp ng\u00e0y 5 th\u00e1ng 11<\/strong> &#8211; l\u1ecbch s\u1eed cho th\u1ea5y \u0111\u00e2y l\u00e0 c\u01a1 h\u1ed9i mua t\u1ed1t nh\u1ea5t<\/li>\n<\/ol>\n<p>Ch\u00e2m ng\u00f4n h\u00e0i h\u01b0\u1edbc d\u00e0nh cho nh\u00e0 giao d\u1ecbch: &#8220;Giao d\u1ecbch RPRX gi\u1ed1ng nh\u01b0 thu ti\u1ec1n b\u1ea3n quy\u1ec1n &#8211; b\u1ea1n mu\u1ed1n c\u00e1c hit ti\u1ebfp t\u1ee5c \u0111\u1ebfn trong khi t\u1eadn h\u01b0\u1edfng thu nh\u1eadp \u1ed5n \u0111\u1ecbnh. Ch\u1ec9 \u0111\u1eebng mong m\u1ed7i qu\u00fd \u0111\u1ec1u l\u00e0 m\u1ed9t b\u1ea3n hit \u0111\u1ee9ng \u0111\u1ea7u b\u1ea3ng x\u1ebfp h\u1ea1ng!&#8221;<\/p>\n<h2>\u2705 C\u00e1ch Mua C\u1ed5 Phi\u1ebfu Royalty Pharma plc (RPRX) &#8211; T\u1eebng B\u01b0\u1edbc<\/h2>\n<table>\n<thead>\n<tr>\n<th>B\u01b0\u1edbc<\/th>\n<th>H\u00e0nh \u0110\u1ed9ng<\/th>\n<th>T\u1ea1i Sao Quan Tr\u1ecdng<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Ch\u1ecdn n\u1ec1n t\u1ea3ng giao d\u1ecbch<\/td>\n<td>\u0110\u1ea3m b\u1ea3o n\u1ec1n t\u1ea3ng c\u00f3 truy c\u1eadp NASDAQ v\u00e0 ph\u00ed h\u1ee3p l\u00fd<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Ho\u00e0n th\u00e0nh x\u00e1c minh t\u00e0i kho\u1ea3n<\/td>\n<td>Th\u00f4ng th\u01b0\u1eddng y\u00eau c\u1ea7u gi\u1ea5y t\u1edd t\u00f9y th\u00e2n v\u00e0 b\u1eb1ng ch\u1ee9ng \u0111\u1ecba ch\u1ec9<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>N\u1ea1p ti\u1ec1n<\/td>\n<td>B\u1eaft \u0111\u1ea7u v\u1edbi s\u1ed1 ti\u1ec1n b\u1ea1n c\u1ea3m th\u1ea5y tho\u1ea3i m\u00e1i khi r\u1ee7i ro<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>T\u00ecm ki\u1ebfm &#8220;RPRX&#8221;<\/td>\n<td>S\u1eed d\u1ee5ng m\u00e3 ch\u1ee9ng kho\u00e1n ch\u00ednh x\u00e1c \u0111\u1ec3 \u0111\u1ea3m b\u1ea3o \u0111\u1ed9 ch\u00ednh x\u00e1c<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>Ch\u1ecdn lo\u1ea1i l\u1ec7nh<\/td>\n<td>D\u00f9ng l\u1ec7nh gi\u1edbi h\u1ea1n \u0111\u1ec3 ki\u1ec3m so\u00e1t gi\u00e1 v\u00e0o<\/td>\n<\/tr>\n<tr>\n<td>6<\/td>\n<td>Xem l\u1ea1i v\u00e0 x\u00e1c nh\u1eadn<\/td>\n<td>Ki\u1ec3m tra m\u1ee9c ph\u00ed hoa h\u1ed3ng tr\u01b0\u1edbc khi ho\u00e0n t\u1ea5t<\/td>\n<\/tr>\n<tr>\n<td>7<\/td>\n<td>Gi\u00e1m s\u00e1t v\u1ecb th\u1ebf<\/td>\n<td>\u0110\u1eb7t c\u1ea3nh b\u00e1o cho m\u1ee5c ti\u00eau gi\u00e1 v\u00e0 \u0111i\u1ec3m d\u1eebng l\u1ed7<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>\ud83d\udca1 T\u1ea1i Sao Pocket Option Ph\u00f9 H\u1ee3p V\u1edbi Nh\u00e0 \u0110\u1ea7u T\u01b0 M\u1edbi<\/h2>\n<p>\u0110\u1ed1i v\u1edbi nh\u1eefng ng\u01b0\u1eddi m\u1edbi b\u1eaft \u0111\u1ea7u h\u00e0nh tr\u00ecnh \u0111\u1ea7u t\u01b0, Pocket Option mang l\u1ea1i nh\u1eefng l\u1ee3i th\u1ebf v\u01b0\u1ee3t tr\u1ed9i:<\/p>\n<ul>\n<li><strong>S\u1ed1 ti\u1ec1n n\u1ea1p t\u1ed1i thi\u1ec3u ch\u1ec9 5 USD<\/strong> &#8211; ho\u00e0n h\u1ea3o \u0111\u1ec3 th\u1eed nghi\u1ec7m chi\u1ebfn l\u01b0\u1ee3c v\u1edbi r\u1ee7i ro th\u1ea5p<\/li>\n<li><strong>Quy tr\u00ecnh KYC nhanh nh\u01b0 ch\u1edbp<\/strong> &#8211; x\u00e1c minh ch\u1ec9 v\u1edbi m\u1ed9t gi\u1ea5y t\u1edd trong v\u00e0i ph\u00fat<\/li>\n<li><strong>H\u00e0ng tr\u0103m ph\u01b0\u01a1ng th\u1ee9c r\u00fat ti\u1ec1n<\/strong> &#8211; t\u1eeb ti\u1ec1n \u0111i\u1ec7n t\u1eed \u0111\u1ebfn ng\u00e2n h\u00e0ng truy\u1ec1n th\u1ed1ng<\/li>\n<li><strong:Giao di\u1ec7n th\u00e2n thi\u1ec7n v\u1edbi ng\u01b0\u1eddi d\u00f9ng<\/strong> &#8211; thi\u1ebft k\u1ebf \u0111\u1eb7c bi\u1ec7t cho ng\u01b0\u1eddi m\u1edbi h\u1ecdc th\u1ecb tr\u01b0\u1eddng<\/li>\n<\/ul>\n<p>R\u00e0o c\u1ea3n gia nh\u1eadp th\u1ea5p c\u1ee7a n\u1ec1n t\u1ea3ng l\u00e0m cho n\u00f3 l\u00fd t\u01b0\u1edfng cho nh\u00e0 \u0111\u1ea7u t\u01b0 mu\u1ed1n x\u00e2y d\u1ef1ng v\u1ecb th\u1ebf t\u1ea1i c\u00e1c c\u00f4ng ty nh\u01b0 Royalty Pharma m\u1ed9t c\u00e1ch t\u1eeb t\u1eeb trong khi h\u1ecdc h\u1ecfi v\u1ec1 \u0111\u1ed9ng l\u1ef1c th\u1ecb tr\u01b0\u1eddng.<\/p>\n<h2>\ud83c\udf0d Royalty Pharma N\u0103m 2025: G\u00e3 Kh\u1ed5ng L\u1ed3 Im L\u1eb7ng Trong T\u00e0i Ch\u00ednh Ch\u0103m S\u00f3c S\u1ee9c Kh\u1ecfe<\/h2>\n<p>Royalty Pharma \u0111\u00e3 c\u00e1ch m\u1ea1ng h\u00f3a c\u00e1ch nh\u00e0 \u0111\u1ea7u t\u01b0 tham gia v\u00e0o \u0111\u1ed5i m\u1edbi d\u01b0\u1ee3c ph\u1ea9m. Thay v\u00ec \u0111\u1eb7t c\u01b0\u1ee3c v\u00e0o ph\u00e1t tri\u1ec3n thu\u1ed1c c\u00e1 nh\u00e2n, c\u00f4ng ty mua quy\u1ec1n b\u1ea3n quy\u1ec1n c\u00e1c li\u1ec7u ph\u00e1p th\u00e0nh c\u00f4ng, t\u1ea1o ra d\u00f2ng thu nh\u1eadp \u0111a d\u1ea1ng t\u1eeb c\u00e1c lo\u1ea1i thu\u1ed1c bom t\u1ea5n tr\u00ean nhi\u1ec1u l\u0129nh v\u1ef1c \u0111i\u1ec1u tr\u1ecb.<\/p>\n<p>C\u00f4ng ty hi\u1ec7n n\u1eafm quy\u1ec1n \u0111\u1ed1i v\u1edbi h\u01a1n 35 s\u1ea3n ph\u1ea9m th\u01b0\u01a1ng m\u1ea1i bao g\u1ed3m \u0111i\u1ec1u tr\u1ecb ung th\u01b0, b\u1ec7nh hi\u1ebfm v\u00e0 c\u00e1c b\u1ec7nh m\u00e3n t\u00ednh. Th\u01b0\u01a1ng v\u1ee5 mua l\u1ea1i quy\u1ec1n Imdelltra tr\u1ecb gi\u00e1 885 tri\u1ec7u USD g\u1ea7n \u0111\u00e2y &#8211; m\u1ed9t li\u1ec7u ph\u00e1p mi\u1ec5n d\u1ecbch \u0111\u1ed9t ph\u00e1 cho ung th\u01b0 ph\u1ed5i t\u1ebf b\u00e0o nh\u1ecf &#8211; th\u1ec3 hi\u1ec7n s\u1ef1 t\u1eadp trung chi\u1ebfn l\u01b0\u1ee3c v\u00e0o c\u00e1c lo\u1ea1i thu\u1ed1c chuy\u1ec3n \u0111\u1ed5i.<\/p>\n<p><strong>S\u1ef1 th\u1eadt th\u00fa v\u1ecb n\u0103m 2025:<\/strong> Danh m\u1ee5c c\u1ee7a Royalty Pharma bao g\u1ed3m b\u1ea3n quy\u1ec1n t\u1eeb c\u00e1c lo\u1ea1i thu\u1ed1c \u0111i\u1ec1u tr\u1ecb kho\u1ea3ng 1 trong 100 b\u1ec7nh nh\u00e2n tr\u00ean to\u00e0n c\u1ea7u. M\u00f4 h\u00ecnh doanh thu c\u1ee7a h\u1ecd th\u1ef1c ch\u1ea5t bi\u1ebfn h\u1ecd th\u00e0nh \u0111\u1ed1i t\u00e1c trong \u0111\u1ed5i m\u1edbi ch\u0103m s\u00f3c s\u1ee9c kh\u1ecfe m\u00e0 kh\u00f4ng ch\u1ecbu r\u1ee7i ro c\u00f4ng ngh\u1ec7 sinh h\u1ecdc truy\u1ec1n th\u1ed1ng!<\/p>\n"},"faq":[{"question":"Royalty Pharma plc (RPRX) l\u00e0 c\u00f4ng ty g\u00ec?","answer":"Royalty Pharma plc l\u00e0 m\u1ed9t c\u00f4ng ty \u0111\u1ea7u t\u01b0 v\u00e0o quy\u1ec1n b\u1ea3n quy\u1ec1n d\u01b0\u1ee3c ph\u1ea9m, ki\u1ebfm l\u1ee3i nhu\u1eadn t\u1eeb c\u00e1c lo\u1ea1i thu\u1ed1c th\u00e0nh c\u00f4ng m\u00e0 kh\u00f4ng ch\u1ecbu r\u1ee7i ro ph\u00e1t tri\u1ec3n thu\u1ed1c truy\u1ec1n th\u1ed1ng."},{"question":"L\u00e0m th\u1ebf n\u00e0o \u0111\u1ec3 mua c\u1ed5 phi\u1ebfu RPRX?","answer":"B\u1ea1n c\u00f3 th\u1ec3 mua c\u1ed5 phi\u1ebfu RPRX th\u00f4ng qua c\u00e1c n\u1ec1n t\u1ea3ng giao d\u1ecbch c\u00f3 truy c\u1eadp s\u00e0n NASDAQ, th\u1ef1c hi\u1ec7n x\u00e1c minh t\u00e0i kho\u1ea3n, n\u1ea1p ti\u1ec1n, t\u00ecm m\u00e3 RPRX, ch\u1ecdn lo\u1ea1i l\u1ec7nh v\u00e0 theo d\u00f5i v\u1ecb th\u1ebf c\u1ee7a m\u00ecnh."},{"question":"R\u1ee7i ro ch\u00ednh khi \u0111\u1ea7u t\u01b0 v\u00e0o Royalty Pharma l\u00e0 g\u00ec?","answer":"C\u00e1c r\u1ee7i ro ch\u00ednh bao g\u1ed3m g\u00e1nh n\u1ee3 l\u1edbn, c\u1ea1nh tranh t\u1eeb thu\u1ed1c generic, kh\u00f4ng ch\u1eafc ch\u1eafn v\u1ec1 ch\u00ednh s\u00e1ch gi\u00e1 thu\u1ed1c v\u00e0 th\u00e1ch th\u1ee9c trong ph\u00e2n b\u1ed5 v\u1ed1n v\u1edbi ch\u01b0\u01a1ng tr\u00ecnh mua l\u1ea1i c\u1ed5 phi\u1ebfu l\u1edbn."},{"question":"Tri\u1ec3n v\u1ecdng gi\u00e1 c\u1ed5 phi\u1ebfu RPRX trong t\u01b0\u01a1ng lai ra sao?","answer":"D\u1ef1 b\u00e1o gi\u00e1 c\u1ed5 phi\u1ebfu RPRX s\u1ebd t\u0103ng l\u00ean 42-46 USD v\u00e0o cu\u1ed1i n\u0103m 2025, ti\u1ebfp t\u1ee5c t\u0103ng trong c\u00e1c n\u0103m sau nh\u1edd m\u00f4 h\u00ecnh kinh doanh \u0111\u1ed9c \u0111\u00e1o v\u00e0 c\u00e1c th\u01b0\u01a1ng v\u1ee5 mua l\u1ea1i chi\u1ebfn l\u01b0\u1ee3c."},{"question":"Nh\u00e0 \u0111\u1ea7u t\u01b0 m\u1edbi n\u00ean l\u00e0m g\u00ec khi b\u1eaft \u0111\u1ea7u v\u1edbi RPRX?","answer":"Nh\u00e0 \u0111\u1ea7u t\u01b0 m\u1edbi n\u00ean b\u1eaft \u0111\u1ea7u v\u1edbi s\u1ed1 ti\u1ec1n nh\u1ecf theo ph\u01b0\u01a1ng ph\u00e1p trung b\u00ecnh gi\u00e1 theo \u0111\u00f4 la, \u0111\u1eb7t c\u1ea3nh b\u00e1o gi\u00e1, ph\u00e2n b\u1ed5 5-10% danh m\u1ee5c cho RPRX v\u00e0 theo d\u00f5i s\u00e1t b\u00e1o c\u00e1o thu nh\u1eadp \u0111\u1ec3 t\u1eadn d\u1ee5ng c\u01a1 h\u1ed9i mua t\u1ed1t."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"Royalty Pharma plc (RPRX) l\u00e0 c\u00f4ng ty g\u00ec?","answer":"Royalty Pharma plc l\u00e0 m\u1ed9t c\u00f4ng ty \u0111\u1ea7u t\u01b0 v\u00e0o quy\u1ec1n b\u1ea3n quy\u1ec1n d\u01b0\u1ee3c ph\u1ea9m, ki\u1ebfm l\u1ee3i nhu\u1eadn t\u1eeb c\u00e1c lo\u1ea1i thu\u1ed1c th\u00e0nh c\u00f4ng m\u00e0 kh\u00f4ng ch\u1ecbu r\u1ee7i ro ph\u00e1t tri\u1ec3n thu\u1ed1c truy\u1ec1n th\u1ed1ng."},{"question":"L\u00e0m th\u1ebf n\u00e0o \u0111\u1ec3 mua c\u1ed5 phi\u1ebfu RPRX?","answer":"B\u1ea1n c\u00f3 th\u1ec3 mua c\u1ed5 phi\u1ebfu RPRX th\u00f4ng qua c\u00e1c n\u1ec1n t\u1ea3ng giao d\u1ecbch c\u00f3 truy c\u1eadp s\u00e0n NASDAQ, th\u1ef1c hi\u1ec7n x\u00e1c minh t\u00e0i kho\u1ea3n, n\u1ea1p ti\u1ec1n, t\u00ecm m\u00e3 RPRX, ch\u1ecdn lo\u1ea1i l\u1ec7nh v\u00e0 theo d\u00f5i v\u1ecb th\u1ebf c\u1ee7a m\u00ecnh."},{"question":"R\u1ee7i ro ch\u00ednh khi \u0111\u1ea7u t\u01b0 v\u00e0o Royalty Pharma l\u00e0 g\u00ec?","answer":"C\u00e1c r\u1ee7i ro ch\u00ednh bao g\u1ed3m g\u00e1nh n\u1ee3 l\u1edbn, c\u1ea1nh tranh t\u1eeb thu\u1ed1c generic, kh\u00f4ng ch\u1eafc ch\u1eafn v\u1ec1 ch\u00ednh s\u00e1ch gi\u00e1 thu\u1ed1c v\u00e0 th\u00e1ch th\u1ee9c trong ph\u00e2n b\u1ed5 v\u1ed1n v\u1edbi ch\u01b0\u01a1ng tr\u00ecnh mua l\u1ea1i c\u1ed5 phi\u1ebfu l\u1edbn."},{"question":"Tri\u1ec3n v\u1ecdng gi\u00e1 c\u1ed5 phi\u1ebfu RPRX trong t\u01b0\u01a1ng lai ra sao?","answer":"D\u1ef1 b\u00e1o gi\u00e1 c\u1ed5 phi\u1ebfu RPRX s\u1ebd t\u0103ng l\u00ean 42-46 USD v\u00e0o cu\u1ed1i n\u0103m 2025, ti\u1ebfp t\u1ee5c t\u0103ng trong c\u00e1c n\u0103m sau nh\u1edd m\u00f4 h\u00ecnh kinh doanh \u0111\u1ed9c \u0111\u00e1o v\u00e0 c\u00e1c th\u01b0\u01a1ng v\u1ee5 mua l\u1ea1i chi\u1ebfn l\u01b0\u1ee3c."},{"question":"Nh\u00e0 \u0111\u1ea7u t\u01b0 m\u1edbi n\u00ean l\u00e0m g\u00ec khi b\u1eaft \u0111\u1ea7u v\u1edbi RPRX?","answer":"Nh\u00e0 \u0111\u1ea7u t\u01b0 m\u1edbi n\u00ean b\u1eaft \u0111\u1ea7u v\u1edbi s\u1ed1 ti\u1ec1n nh\u1ecf theo ph\u01b0\u01a1ng ph\u00e1p trung b\u00ecnh gi\u00e1 theo \u0111\u00f4 la, \u0111\u1eb7t c\u1ea3nh b\u00e1o gi\u00e1, ph\u00e2n b\u1ed5 5-10% danh m\u1ee5c cho RPRX v\u00e0 theo d\u00f5i s\u00e1t b\u00e1o c\u00e1o thu nh\u1eadp \u0111\u1ec3 t\u1eadn d\u1ee5ng c\u01a1 h\u1ed9i mua t\u1ed1t."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>C\u00e1ch mua c\u1ed5 phi\u1ebfu Royalty Pharma plc (RPRX) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Royalty Pharma plc (RPRX)<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-royalty-pharma\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"C\u00e1ch mua c\u1ed5 phi\u1ebfu Royalty Pharma plc (RPRX) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Royalty Pharma plc (RPRX)\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-royalty-pharma\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-28T12:25:46+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-royalty-pharma\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-royalty-pharma\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"C\u00e1ch mua c\u1ed5 phi\u1ebfu Royalty Pharma plc (RPRX) &#8211; \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Royalty Pharma plc (RPRX)\",\"datePublished\":\"2025-08-28T12:25:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-royalty-pharma\/\"},\"wordCount\":23,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-royalty-pharma\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals15-scaled.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"vt-VT\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-royalty-pharma\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-royalty-pharma\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-royalty-pharma\/\",\"name\":\"C\u00e1ch mua c\u1ed5 phi\u1ebfu Royalty Pharma plc (RPRX) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Royalty Pharma plc (RPRX)\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-royalty-pharma\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-royalty-pharma\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals15-scaled.webp\",\"datePublished\":\"2025-08-28T12:25:46+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-royalty-pharma\/#breadcrumb\"},\"inLanguage\":\"vt-VT\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-royalty-pharma\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"vt-VT\",\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-royalty-pharma\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals15-scaled.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals15-scaled.webp\",\"width\":2560,\"height\":1429},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-royalty-pharma\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/vt\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"C\u00e1ch mua c\u1ed5 phi\u1ebfu Royalty Pharma plc (RPRX) &#8211; \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Royalty Pharma plc (RPRX)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/vt\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/vt\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"vt-VT\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"vt-VT\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/vt\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Royalty Pharma plc (RPRX) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Royalty Pharma plc (RPRX)","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-royalty-pharma\/","og_locale":"en_US","og_type":"article","og_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Royalty Pharma plc (RPRX) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Royalty Pharma plc (RPRX)","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-royalty-pharma\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-28T12:25:46+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-royalty-pharma\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-royalty-pharma\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/vt\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Royalty Pharma plc (RPRX) &#8211; \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Royalty Pharma plc (RPRX)","datePublished":"2025-08-28T12:25:46+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-royalty-pharma\/"},"wordCount":23,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-royalty-pharma\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals15-scaled.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"vt-VT","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-royalty-pharma\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-royalty-pharma\/","url":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-royalty-pharma\/","name":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Royalty Pharma plc (RPRX) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Royalty Pharma plc (RPRX)","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/vt\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-royalty-pharma\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-royalty-pharma\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals15-scaled.webp","datePublished":"2025-08-28T12:25:46+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/vt\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-royalty-pharma\/#breadcrumb"},"inLanguage":"vt-VT","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-royalty-pharma\/"]}]},{"@type":"ImageObject","inLanguage":"vt-VT","@id":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-royalty-pharma\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals15-scaled.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals15-scaled.webp","width":2560,"height":1429},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-royalty-pharma\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/vt\/"},{"@type":"ListItem","position":2,"name":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Royalty Pharma plc (RPRX) &#8211; \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Royalty Pharma plc (RPRX)"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/vt\/#website","url":"https:\/\/pocketoption.com\/blog\/vt\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/vt\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"vt-VT"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/vt\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"vt-VT","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/vt\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"vt_VT","wpml_translations":{"pt_AA":{"locale":"pt_AA","id":354691,"slug":"how-to-buy-royalty-pharma","post_title":"Como comprar a\u00e7\u00f5es da Royalty Pharma plc (RPRX) - Investimento em a\u00e7\u00f5es da Royalty Pharma plc (RPRX)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-royalty-pharma\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/vt\/wp-json\/wp\/v2\/posts\/354693","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/vt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/vt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/vt\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/vt\/wp-json\/wp\/v2\/comments?post=354693"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/vt\/wp-json\/wp\/v2\/posts\/354693\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/vt\/wp-json\/wp\/v2\/media\/334117"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/vt\/wp-json\/wp\/v2\/media?parent=354693"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/vt\/wp-json\/wp\/v2\/categories?post=354693"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/vt\/wp-json\/wp\/v2\/tags?post=354693"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}